Skip to main content

Hls Therapeutics Inc(HLS-T)
TSX

Today's Change
Real-Time Last Update

Closing Bell: Hls Therapeutics Inc down on Friday (HLS)

Automated Summaries - The Globe and Mail - Fri Apr 26, 4:02PM CDT

In today's trading, shares of Hls Therapeutics Inc opened at $4.40 and closed at $4.65. Intraday prices ranged from a low of $4.40 to a high of $4.66.

The price eased -1.69% from the previous day's close of $4.73.

Today across North America, the TSX Composite closed 0.38% at 21969.24, the S&P 500 closed -0.46% at 5048.42, the Dow Jones Industrial Average closed -0.98% at 38085.80 and the Nasdaq Composite closed -0.64% at 15611.76.

Hls Therapeutics Inc has listed on the Toronto Stock Exchange (TSX) under the ticker HLS.

A total of 700 shares was traded during the session, with total trades of 7, while having an average volume of 3,133 over 5 days.

The TSX market on the whole today saw 3,324 price advancers against 1,856 declines and 124 unchanged.

During the prior 52 weeks, HLS.TO has traded as high as $7.12 (July 17,2023) and low as $3.34 (November 27,2023). Moreover, the shares have shrunken -19.55% in the last 52 weeks, while this year, they have boosted 17.72%.

It announced a 0.05 dividend on March 15/23, with an April 27/23 ex-date and June 15/23 pay day.

Following today's trading, Hls Therapeutics Inc has a market capitalization of $150.82 million on a float of 31,886 shares outstanding. Its annual EPS is $-0.85.

Hls Therapeutics Inc is a TSX Drug Specialty & Generic company headquartered in Etobicoke, CAN.

Hls Therapeutics Inc's average recommendation is "Moderate Buy" based on 5.00 analysts according to Zacks. Currently, there are 3 buy ratings and 2 hold ratings for the stock.

AI at The Globe and Mail
This report is produced using automated technology that summarizes market data into articles for our readers. Ongoing project experiments that leverage artificial intelligence include valuation screens across 14 categories and end-of-day Closing Summary reports for all North American securities..

More from The Globe